Vivosim Labs, Inc. (VIVS) Stock Price & Analysis
Vivosim Labs, Inc. (VIVS) rose 0.00% to USD 1.19 as of June 10, 2026 at 00:35 UTC, according to Nexqual real-time market data.
VIVS last closed at USD 1.19; the session ranged USD 1.13–1.21 on volume of 38,070 shares. Market capitalization is $3.44M, with a 52-week range of USD 1.13–5.3 (NCM). Source: Nexqual, June 10, 2026 at 00:35 UTC.
Key Statistics (as of June 10, 2026 at 00:35 UTC)
| Price | USD 1.19 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.19 |
| Open | USD 1.21 |
| Day Range | USD 1.13 – 1.21 |
| 52-Week Range | USD 1.13 – 5.3 |
| Volume | 38,070 shares |
| Market Cap | $3.44M |
| Exchange | NCM |
Technical Analysis (VIVS)
Nexqual's technical model rates VIVS "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 00:35 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.18 (neutral) |
| vs SMA50 | Below (USD 1.41) |
| MACD | -0.06 (negative) |
Analyst Ratings (VIVS)
Wall Street analysts rate VIVS "None", per Nexqual as of June 10, 2026 at 00:35 UTC.
| Consensus Rating | None |
|---|
Earnings (VIVS)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2024-12-31 | USD -2.28 vs est -2.4 ▲ beat |
| 2024-09-30 | USD -1.68 vs est -2.64 ▲ beat |
| 2024-06-30 | USD -2.76 vs est -3.96 ▲ beat |
| 2024-03-31 | USD -8.04 vs est -5.04 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:35 UTC.
Financials & Fundamentals (VIVS)
| Total Revenue | $142,000 |
|---|---|
| Revenue Growth (YoY) | +8.30% |
| Gross Margin | +0.00% |
| Operating Margin | -10576.92% |
| Profit Margin | +0.00% |
| ROE | -51.07% |
| Debt / Equity | 18.28 |
| Current Ratio | 2.44 |
| Total Cash | $4.29M |
| Total Debt | $812,000 |
| Free Cash Flow | $-7.90M |
Source: Nexqual, June 10, 2026 at 00:35 UTC.
Financial Health Score (VIVS)
Nexqual rates Vivosim Labs, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:35 UTC.
| Growth | Solid — Revenue +8% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -51%, ROA -132.5% |
Ownership (VIVS)
| Insider Ownership | +14.80% |
|---|---|
| Institutional Ownership | +7.81% |
| Shares Outstanding | 2.89M |
| Float | 2.33M |
| Short % of Float | +1.16% |
Source: Nexqual, June 10, 2026 at 00:35 UTC.
Leadership (VIVS)
Vivosim Labs, Inc. is led by Keith E. Murphy (age 53), Executive Chairman & Corporate Secretary, per Nexqual as of June 10, 2026 at 00:35 UTC.
| Executive Chairman & Corporate Secretary | Keith E. Murphy (age 53) |
|---|---|
| President, CFO & Principal Financial Officer | Norman Staskey (age 55) |
| Chief Scientific Officer | Amar A. Sethi |
Major Backers & Investors (VIVS)
Notable institutional backers of Vivosim Labs, Inc. include Fidelity, Goldman Sachs, Citigroup Inc., according to Nexqual as of June 10, 2026 at 00:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.14% |
| Goldman Sachs | 0.62% |
| Citigroup Inc. | 0.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.45% |
| Geode Capital | 1.41% |
| BlackRock | 0.45% |
Source: Nexqual, June 10, 2026 at 00:35 UTC.
From Vivosim Labs, Inc.'s Latest SEC 10-K Filing (filed 2025-06-05)
Key Strengths & Strategy (as disclosed to the SEC)
- VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
- It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
- The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease.
- In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SSYS | Stratasys, Ltd. | USD 8.66 | ▼ 2.15% |
| DDD | 3D Systems Corporation | USD 2.95 | ▲ 1.37% |
| PRLB | Proto Labs, Inc. | USD 75.48 | ▲ 3.91% |
| MTLS | Materialise NV | USD 6.63 | ▲ 1.07% |
| SYRS | Syros Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:35 UTC. This page is informational and not investment advice.